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PERBANDINGAN PROTEOM ANTARA Mycobacterium tuberculosis AVIRULEN 
H37Ra DENGAN Mycobacterium tuberculosis VIRULEN H37Rv 
 
ABSTRAK 
M. tuberculosis H37Ra adalah strain terbitan daripada strain virulen H37 yang dijumpai 
pada tahun 1935. Bagi mengenalpasti faktor-faktor virulen untuk M. tuberculosis H37Rv, 
proteom- proteom strain virulen yang dihasilkan melalui elektroforesis gel dua-dimensi 
pada tiga jangka masa kultur yang berbeza (14, 28 dan 50 hari) telah dibandingkan 
dengan proteom bagi strain avirulen M. tuberculosis H37Ra. Sejumlah 250 tompok 
protein telah dikenalpasti selepas pewarnaan Coomassie Blue dan proteom M. 
tuberculosis H37Rv dan M. tuberculosis H37Ra adalah hampir sama (R2~0.70), tiga 
puluh satu tompok protein yang menunjukkan perbezaan ekspreksi pada tempoh 14, 28 
dan 50 hari pertumbuhan telah dikenalpasti, iaitu 14 tompok protein daripada ekstraksi 
Tris dan 17 tompok protein daripada ekstraksi TLB. Daripada 26 tompok protein yang 
dianalisis dengan mengunakan LC-MS/MS, 32 protein telah dikenalpasti. L-guluno-1,4-
laktone dehidrogenase (Rv1771) menunjukkan peningkatan-regulasi pada hari ke-14 
untuk M. tuberculosis H37Rv sahaja. Tiga protein menunjukkan perbezaan ekspresi pada 
hari ke-28 untuk M. tuberculosis H37Rv, iaitu protein hipotetikal terabadi Acg (acg, 
Rv2032), pengangkut makrolida, protein pengangkut kaset pengikat ATP (pengangkut 
ABC, Rv2477c) dan asid-lemak-CoA ligase (fadD28, Rv2941). Acg yang terlibat dalam 
dormasi regulon menunjukkan penurunan-regulasi dalam M. tuberculosis H37Rv. 
Rv2477c dan fadD28 pula menunjukkan peningkatan-regulasi dalam M. tuberculosis 
H37Rv. M. tuberculosis menunjukkan kerintangan terhadap antibiotik umum, hal ini 
mungkin disebabkan oleh kehadiran beberapa pengangkut ABC pada membran sel M. 
tuberculosis yang boleh membawa antibiotik keluar daripada sel. Penurunan-regulasi 
protein fadD28 yang terlibat dalam biosintesis dinding sel membawa implikasi 
xv 
 
kelemahan pertumbuhan M. tuberculosis H37Ra secara intraselular. Kajian ini memberi 
maklumat proteom untuk M. tuberculosis H37Rv dan M. tuberculosis H37Ra dan 
perbezaan ekspresi protein antara kedua-dua strain ini boleh memberi pemahaman yang 
lebih baik tentang fenotip dan mekanisme pathogenesis antara M. tuberculosis H37Rv 
dengan strain tak virulen M. tuberculosis H37Ra. Penyiasatan lanjutan ke atas protein-
protein yang dilaporkan mungkin dapat membantu dalam perkembangan biopenanda 
yang berpontensi untuk tujuan diagnostik dan pengubatan penyakit tuberkulosis.  
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COMPARISON OF PROTEOMES OF AVIRULENT Mycobacterium tuberculosis 
H37Ra AND VIRULENT Mycobacterium tuberculosis H37Rv 
ABSTRACT 
M. tuberculosis H37Ra, which was discovered in 1935, was derived from the virulent 
strain H37. In order to identify the factors that are correlated to virulence in M. 
tuberculosis H37Rv, 2D-gel profile of three virulent strains at culture grown for three 
time points (14, 28 and 50 days) were compared with its avirulent counterpart M. 
tuberculosis H37Ra. A total of 250 protein spots were visualized by Coomassie blue 
staining. The protein profiles of the M. tuberculosis H37Rv and M. tuberculosis H37Ra 
were highly similar (R2~0.70), thirty one spots were found to be differentially expressed 
at 14, 28 and 50 days cultures, whereby 14 spots were identified from Tris extract and 17 
spots were identified from TLB extract. Twenty-six spots could be identified by 
LCMS/MS and showed to consist of 32 proteins. L-guluno-1,4-lactone dehydrogenase 
(Rv1771) was significantly up-regulated in 14-day culture of M. tuberculosis H37Rv 
only. Three proteins showed differential expression in 28-day culture only. These 
proteins include the conserved hypothetical protein Acg (acg, Rv2032), macrolide-
transport ATP-binding cassette protein (ABC transporter, Rv2477c) and fatty-acid-CoA 
ligase (fadD28, Rv2941). Acg which is involved in dormancy regulon was down-
regulated in M. tuberculosis H37Rv. Rv2477c and fadD28 were up-regulated in M. 
tuberculosis H37Rv. M. tuberculosis is usually resistant to common antibiotics; this may 
be due to the presence of several ABC transporters on the cell membrane that could 
transport the antibiotics out from cells. Down-regulation of fadD28, which is involved in 
cell wall biosynthesis, may explain the low survival of M. tuberculosis H37Ra 
intracellularly. This work has provided the information on the proteome of M. 
tuberculosis H37Rv and M. tuberculosis H37Ra, the differential protein expression 
between the two strains may give a better understanding on phenotypic and pathogenesis 
xvii 
 
between M. tuberculosis H37Rv and its avirulent counterpart M. tuberculosis H37Ra. 
Further investigation on the reported proteins may also lead to identification of candidate 
biomarkers for diagnosis and treatment of the disease. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 The historical background and the present burden of the tuberculosis 
disease  
Tuberculosis (TB) is an ancient disease (Daniel, 2006). It is known to be one of 
the most persistent diseases of mankind. TB causes illness and death in a wide 
geographical area (Figure 1.1). The first evidence of TB in human was detected in 
Egyptian mummies dated from 2400 B.C. whereby the identified microbial genetic 
material recovered from the bone tissues was shown to be similar to that of 
Mycobacterium genetic material (Morse et al., 1964; Zimmerman, 1979; Crubéy et al., 
1998). 
 
 
Figure 1.1 The global incidence of TB. The number of new TB cases per 100,000 
populations for the year 2008 according to WHO report (Adapted from WHO, 2009). 
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Around 460 B.C., a term ‘phthsis’ was used to describe TB. Hippocrates stated 
that ‘phthsis’ is the most widespread disease of that time. Later, Aristotle (382 to 322 
B.C) and Galen (130 to 200 A.D) reported that TB can be transmitted from man to man. 
Hence, TB epidemic which is known as ‘white plague’ was a dreadful threat during the 
17th and 18th centuries in Europe.  
 
In the period from 1483 to 1553, Frascatrius suggested that the mode of TB 
transmission from human to human is via aerosol. In 1865, a French military doctor, 
Jean-Antoine Villemin, performed an experiment by infecting rabbits with liquids from 
tuberculosis cavities. Indeed, the first breakthrough of understanding TB was reported by 
a German bacteriologist, Robert Koch in 1882. He has isolated the infectious agent of 
tuberculosis and then infected the disease to animals. Later, he had also developed a 
staining method for the infectious agent and examined a rod shaped agent under 
microscope (Koch, 1882; Kaufmann, 2003; Daniel, 2005). Later, he further discovered a 
compound, named tuberculin which could be used as an agent to diagnose TB. The 
tuberculin skin test is still used today with some modifications (Kaufmann and Schaible, 
2005). In 1896, Lehmann and Newman classified this organism as Mycobacterium genus 
that belonged to Mycobacteriaceae family (Ridley, 1981). 
 
Between 1908 and 1920, an attenuated strain derived from Mycobacterium bovis 
(M. bovis) was developed by two Frenchmen (Calmette and Guérin). M. bovis is a 
species closely related to M. tuberculosis that was found in cattle. Nearly 200 times of 
subculturing of virulent M. bovis, resulting in the discovery of attenuated strain called 
Bacillus Calmette-Guérin (BCG) and this has served as a vaccine against tuberculosis 
(Barreto et al., 2006). 
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With the advent of BCG vaccination, the disease was substantially under control, 
although it was not totally eliminated. In 1985, the rapid increase of new TB cases 
globally urged WHO to declare tuberculosis as a ‘global emergency’ and subsequently 
WHO implemented controlled TB plan in 1993 (WHO, 1993). The resurgence of TB 
cases was partly due to the increased urbanization, civil wars, mass migration of 
population, homeless individuals and the HIV epidemic (Frieden et al., 2003). WHO 
estimated that eight million people will be infected with TB yearly, of which 95 % of 
these cases would be from developing countries. WHO also estimated that two millions 
people will die of TB yearly. In order to actively prevent the spread of TB, WHO and 
Stop TB Partnership endorsed a global plan to reduce TB prevalence and mortality by 
2015 and to eliminate TB by 2050 (WHO, 2006). 
 
In spite of the global preventive TB plan, the disease remains as an alarming 
public health problem. This is also partly due to the emergence of multi-drug (MDR) and 
extremely drug (XDR) resistance TB cases. Multi drug resistance TB is defined as TB 
caused by strains resistant to the first line anti-TB drugs, such as isoniazid and rifampicin 
(Dye et al., 2002), whereas XDR-TB is defined as MDR-TB that is also further resistant 
to several main classes of the second line anti-TB drugs, such as fluoroquinolones 
(Raviglione and Smith, 2007). All these problems reflect the importance of an intensive 
research to investigate: 
 
a) an effective TB vaccine for prevention. 
b) an effective anti-TB medication for treatment.  
c) an improvement of the current diagnosis of TB.  
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1.2 Tuberculosis in Malaysia 
 In the early 1940s and 1950s, TB was the main contagious disease in Malaysia. 
Although there was effective chemotherapy for TB in late 1950s, yet TB remained as a 
major cause of mortality at that time. The Malaysian government realized the seriousness 
of TB and launched the National TB Control Program (NTP) in 1961. At that time, a 
combination of three drugs regime was recommended and the duration of treatment was 
1-2 years. Streptomycin, isoniazid and paraaminosalicylic acid (PAS) were administered 
for the first two months, followed by isoniazid and PAS for the next 12 months. 
Furthermore, school children were vaccinated by BCG vaccination (Figure 1.2).  
 
 
Figure 1.2 The coverage rate (%) of BCG vaccination in Malaysia from 1993 to 2006 
(Adapted from Venugopalan, 2007). 
 
 
 
The headquarters of National TB Centre is located in Kuala Lumpur while the 
state general hospitals with chest clinics functioned as the state directorates. The state 
directorate is known as the State TB Managerial Team; this team is mainly responsible 
for the implementation of the activities of the NTP at the state and district levels. Owing 
to the proper control prevention strategy, TB cases were dramatically reduced recently.  
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 The resurgence of TB is mainly due to human immunodeficiency virus (HIV) in 
Malaysia (Figure 1.3). In 1990, the number of TB/HIV co-infection cases has escalated 
and the number of deaths due to TB/HIV co-infections has increased. In 1996, 329 
TB/HIV co-infection cases were reported compared to 6 cases reported in 1991. The 
National TB Centre has now been renamed as The Institute of Respiratory Medicine. In 
2007, TB was one of the top 5 prominent infectious diseases, therefore WHO classified 
Malaysia as an intermediate-TB-burden country.  
 
 
Figure 1.3 The cases of TB, HIV, TB/HIV in Malaysia from 1986 to 2007 (Adapted 
from Venugopalan, 2009). 
 
1.3 The structure of Mycobacteria cell envelope 
Mycobacterium is a non-motile and non-sporulated rod-shaped bacterium. The 
bacteria are closely related to Actinomycetes with high lipid content in the cell wall 
(Bloom, 1994; Kolattukudy et al., 1997). The cell envelope of Mycobacterium comprises 
of plasma membrane, cell wall and outer like capsule layer (Figure 1.4). 
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Figure 1.4 Structure of the cell envelope of Mycobacteria (Adapted from Brennan 
and Crick, 2007). 
 
1.3.1 Plasma membrane 
 The plasma membrane of Mycobacteria contains some lipopolysaccharides that 
provides osmotic protection, regulates the traffic of specific solutes between the 
cytoplasm and the environment, and also organizes the cell house-keeping tasks 
(Mahapatra et al., 2005). 
 
1.3.2 Cell wall 
The cell wall of Mycobacteria is very unique and is associated with pathogenicity 
of M. tuberculosis. The innermost cell wall layer is peptidoglycan, which is responsible 
for shape-forming property and the structural integrity of the bacterium. The building 
block of peptidoglycan layer in Mycobacteria consists of N-glycolyl muramic acid units 
7 
 
(Crick et al., 2001). The arabinogalactan layer is covalently bound to peptidoglycan. The 
surface of arabinogalactan layer has mycolic acids that are typically long and branches 
carbon chains containing 60- to 90- carbon atoms. The outer layer of the cell wall 
consists of an array of free lipids such as phthiocerol dimycoserosates (PDIM), phenolic 
glycolipids (PGL), trehalose-containing glycolipids and sulfolipids (SL). Some 
glycolipids are anchored to the plasma membrane and extended to the exterior of the cell 
wall such as the phosphatidyl-myoinositol mannosides, lipomannan (LM) and 
lipoarabinomanan (LAM). These fatty acids and lipids pose Mycobacteria virulence. 
Furthermore, they protect the bacteria against some antibiotics and from the immune 
system of the host (Chatterjee and Khoo, 1998; Takayama et al., 2005). 
 
Interspersed proteins are also found in Mycobacteria cell wall, some of these 
proteins are responsible for the construction of Mycobacteria cell wall. For example, 
porins form hydrophilic channels which allow the aqueous solutes to enter the mycolic 
acid layer (Brennan and Nikaido, 1995). 
 
1.3.3 Outer capsule like layer  
Polysaccharides, proteins and certain extractable lipids are found in the outer-
most capsule (Brennan and Nikaido, 1995). Hence, the lipid and fatty acid biosynthetic 
pathways in Mycobacteria hold the potential study of cell membrane and wall proteins 
because they may be involved in virulence pathogenesis.  
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1.4 Mycobacteria growth and metabolism 
1.4.1 Growth 
Mycobacteria are divided into two groups namely rapid-growing and slow-
growing Mycobacterium species. Rapid-growing Mycobacteria consists of M. smegmatis 
and M. fortuitum (doubling time is ~ 2 to 3 hrs) whereas slow-growing Mycobacteria are 
M. avium-intracellulare complex (doubling time ~ 10 to 12 hrs), M. tuberculosis 
complex (doubling time ~ 22 to 24 hrs) and M. leprae (doubling time ~ 14 days in vivo).  
 
Mycobacterium is prototrophic (i.e. it can synthesize all its components from 
basic carbon and nitrogen sources) and heterotrophic (i.e. it uses synthetic organic 
compounds as a source of carbon and energy). Most of the Mycobacterium requires 
carbon source, nitrogen source and essential metal ions such as iron and magnesium for 
propagation. In general, a simple growth medium contains all of these sources.  
 
M. tuberculosis multiplies slowly in every 12 to 24 hours even under favorable 
laboratory conditions. This is partially due to the cell wall impermeability that limits 
nutrient uptake (Chauhan et al., 2006). The life cycle of M. tuberculosis depends on the 
nutritional quality of the environment, either in the natural habitat or in the culture media. 
A high concentration of fatty acids slows down the growth of Mycobacterium. 
 
1.4.2 Metabolism 
M. tuberculosis has the ability to synthesize the essential amino acids, vitamins 
and enzyme co-factors (Bloom, 1994). The enzymes for essential pathways such as 
glycolysis, pentose phosphate pathway, tricarboxylic acid and glyoxylate cycles are 
found in M. tuberculosis (Koníček, 1984). 
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Under aerobic respiration, M. tuberculosis produces ATP from oxidative 
phosphorylation, which involves a ubiquinone cytochrome b reductase complex and 
cytochrome c oxidase. Nevertheless, M. tuberculosis can survive in anaerobiosis due to 
the presence of several anaerobic phosphorylative electron transport chains in 
mitochondrial membrane. M. tuberculosis conducts different physiological pathways 
during the change in environment. A study reported that M. tuberculosis is capable of 
alternating the metabolism from aerobic and carbohydrate-metabolizing mode to 
microaerophilic and lipids-utilizing mode (Segal and Bloch, 1956). 
 
1.5 Pathogenesis of tuberculosis 
TB is a transmissible disease, affecting various parts of body’s tissues especially 
the lung. The lung is the main entrance of M. tuberculosis. Generally the infection can be 
subdivided into 5 stages as below: 
 
1.5.1  Stage I of M. tuberculosis infection 
When a person inhales aerosol droplets, the larger droplets (> 0.5 µm) are lodged 
in the upper respiratory tract (the nose and throat) but the smaller droplets (< 0.5 µm) 
may reach the alveoli. In the alveolar space, the bacteria encounter polymorphonuclear 
granulocytes (PMNs) and inactive macrophages (Persson et al., 2009). Hence, the initial 
infection begins.  
 
1.5.2 Stage II of M. tuberculosis infection 
Between 1-3 weeks after initial infection, M. tuberculosis stays dormant and 
replicates freely within the inactive macrophages. Due to this, the other macrophages 
from peripheral blood will gather at the infection site, these inactive macrophages will try 
to phagocytose M. tuberculosis. In order to survive within the inactive macrophage, M. 
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tuberculosis has to overcome intra-phagosomal degradation from the fusion of 
phagolysosome (Armstrong and Hart, 1975), thus delaying apoptosis (Zhang et al., 2005; 
Chen et al., 2006). In other words, these inactive macrophages cannot diminish M. 
tuberculosis.  
 
1.5.3 Stage III of M. tuberculosis infection 
In order to activate macrophages to destroy M. tuberculosis, the cell-mediated 
immune system has to be triggered. The lymphocytes such as T-cells will infiltrate the 
infection site. T-cells will recognize the M. tuberculosis antigens which have been 
processed and presented by major histocompatibility complex (MHC) molecules. As a 
result, T- cell is activated and produce cytokines such as gamma interferon (IFN). IFN 
will activate the inactive macrophage and promote M. tuberculosis destruction (Smith, 
2003). 
 
At this stage, patients infected by TB will show positive tuberculin skin test due 
to the vigorous cell-mediated immune response (Puri and John, 1997). M. tuberculosis, 
an intracellular pathogen, can only be controlled by cell-mediated immune system. In 
addition, activation of macrophages results in the synthesis of lytic enzymes and reactive 
intermediates. These compounds are the major impact on the immune pathology. 
Tubercle formation begins at this stage, and the center of tubercle contains cheesy-semi-
solid materials known as caseation necrosis. M. tuberculosis cannot duplicate within 
these tubercles because of the low pH and anoxic environment. However, some M. 
tuberculosis can persist within these tubercles for a long period of time (Grosset, 2003). 
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1.5.4 Stage IV of M. tuberculosis infection 
After the activation of macrophages, the tubercles will be surrounded by many 
activated macrophages and also inactivate macrophages. The persistence M. tuberculosis 
in tubercles will start to duplicate in the inactivate macrophage and hence the tubercle is 
enlarged. M. tuberculosis in the enlarged tubercle can invade the bronchus through 
hematogenic route. Eventually, M. tuberculosis disseminate to various parts of the body 
through hematogenic and lymphatic route. This infection is known as extrapulmonary TB.  
The secondary lesions caused by extrapulmonary TB can be categorized into: 
 
a) Exudative lesions involve the accumulation of polymorphonuclear granulocytes 
(PMNs) around the tissue infected with M. tuberculosis which can propagate 
freely.  The result of such situation is the formation of ‘soft tubercle’.  
 
b) Granulomatous or productive lesions take place when the host becomes 
hypersensitive to tuberculoproteins.  The consequence of this is the formation of 
‘hard tubercle’. 
 
1.5.5 Stage V of M. tuberculosis infection 
The caseous center of the tubercles is enlarged and liquefied through an unknown 
process (Bentrup and Russell, 2001). The liquid from the surrounding tissues provides 
nutrient for the growth of M. tuberculosis. The antigens from M. tuberculosis bind to the 
walls of bronchi and cause necrotic and rupture. A cavity is formed at this stage, 
resulting in local or systemic TB disease.  
 
In fact, only a very small percentage of M. tuberculosis infections cause the 
disease, and even a smaller percentage advance to a stage of being uncontrollable or 
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serious. For a person who has effective cell-mediated immunity, the granulomas heal, 
become fiborous and calcify from the lesions. This substance is called Ghon complex. 
Thus, recovery from the TB disease is probable. 
 
A small number of M. tuberculosis may also calcify from metastatic foci. 
However, the escaped M. tuberculosis can survive in the foci and subsequently reactivate 
the M. tuberculosis over a certain period of time, which is known as latent infection 
(Pandey and Sassetti, 2008) (Figure 1.5). 
 
Figure 1.5 The possible outcomes of M. tuberculosis exposure (Adapted from Målen, 
2007). 
 
1.6 Diagnosis and Anti-TB therapy of the disease 
1.6.1  Active TB 
Active TB is the detection of M. tuberculosis complex bacilli from respiratory 
tract (pulmonary TB) specimens or specimens from extrapulmomary TB. The common 
and inexpensive diagnosis methods of active TB are Zielh-Neelsen (ZN) staining and 
culture on solid or liquid medium. Zielh-Neelsen (ZN) staining is simple, fast, 
inexpensive and very usable diagnosis method for the contagious patients. Due to the low 
sensitivity and specificity of ZN staining in low Mycobacteria loads specimen, the 
culture diagnosis methods are used to examine the specimen for the drug susceptibility 
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test and cross contamination of the Mycobacterium genus. Cultivation of M. tuberculosis 
required 6 weeks or longer on solid culture media (e.g the egg-based Lowenstein-Jensen 
medium or the agar-based Middlebrook 7H10 or 7H11) whereas observed growth of M. 
tuberculosis in liquid culture media takes 7-21 days only (e.g Middlebrook 7H9) 
(Morgan et al., 1983). Both solid and liquid media are required, the former is to examine 
the colony morphology and the latter is for advanced molecular diagnostic assays. In 
addition, ZN staining and the culture diagnosis methods are also used in monitoring the 
effectiveness of the direct observed therapy strategy (DOTS). 
 
In addition to active TB, a variety of new molecular diagnostic assays are 
developed for rapid diagnosis of TB and other Mycobacteria diseases: 
 
a) Immunological tests 
Immunological tests based on the interaction of antigen with the antibodies from 
the serum active TB patient. ELISA-based serological tests and immunochromatographic 
assays can easily be administered to TB patients in low resource countries as they are 
rapid and inexpensive (Chan et al., 2000) ELISA–based serological test is used to detect 
specific TB antibodies which are bound to various purified or complex antigens of M. 
tuberculosis (Chan et al., 2000; Gennaro, 2000; Silva et al., 2003; Kanaujia et al., 2005; 
Weldingh et al., 2005). However, due to large variations observed in the interaction 
between antibodies from tuberculosis patients and Mycobacteria antigens, an 
improvement in sensitivity and specificity of ELISA- based serogical test is required 
(Lyashchenko et al., 1998; Abebe et al., 2007). Another immunochromatographic assay is 
known as lateral-flow tests or simple strip tests. The benefits of immunochromatographic 
tests include: 1) user-friendly; 2) fast result; 3) long-term stability over different climates; 
4) relatively inexpensive.   
14 
 
b) Nucleic acid amplification assays 
 
Nucleic acid amplification assays are polymerase chain reaction (PCR), 
transcription-mediated amplification (TMA) and strand displacement amplification 
(SDA). These techniques are used to detect nucleic acid of microorganisms and have 
high sensitivity (95 %) and specificity (98 %) result (Boman et al., 1999). However, these 
assays may give false positive result in people who had TB previously; this is due to the 
high sensitivity of the assays that could detect the residual of genetic material from the 
previous infection. Nevertheless, these assays are not very practical in field study and 
expensive.  
 
1.6.2  Latent tuberculosis 
Tuberculin skin test is a delayed-type hypersensitivity test which comprises a 
cocktail of purified M. tuberculosis antigens, known as purified protein derivatives 
(PPD). It can detect active TB disease or TB infection. A person, who is infected with M. 
tuberculosis for a duration of 6-8 weeks may be presented with positive result of 
tuberculin skin test. An intradermal injection of PPD is administered and the induration 
period will be recorded after 48 to 72 hours. The effects of the local injection site within 
24 to 72 hours are induration, swelling and monocytic infiltration. An induration is the 
diameter measurement of hard swelling site of tuberculin skin reaction. Enarson (2004) 
reported that a person who has induration tuberculin skin test greater than 10 mm may 
develop TB easily in the future. An induration result of 20 mm or more indicates that a 
person has active TB disease. However, a false positive result is shown when the purified 
protein derivatives interact with BCG vaccine and other common Mycobacteria in the 
environment (Iseman, 2007). 
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In the last decade, interferon-gamma (IFN- γ) assays suitable for detecting TB 
infection have been developed. M. tuberculosis antigens [(early secretory antigenic 
target-6 (ESAT-6) and culture filtarte protein-10 (CFP-10)] will respond to IFN-γ 
production by T-lymphocytes (Doherty et al., 2002) and produce positive result. These 
tests are more specific compared to tuberculin skin test for latent TB (Brook et al., 2001) 
as they are not affected by BCG vaccine (Lalvani et al., 2001). 
 
Currently, IFN- γ assays are commercially available. They are the enzyme-linked 
immunospot (ELISPOT) T SPOT-TB assay (Oxford Immunotec, Oxford, United 
Kingdom) and the QuantiFERON-TB Gold (Cellestis International, Carnegie, Australia). 
Both of these tests are approved by Food and Drug Administration (FDA) for detecting 
latent TB infection in Europe and USA (Mazurek et al., 2003; Meier et al., 2005). 
QuantiFERON-TB Gold test is a quantification test of IFN- γ released from T 
lymphocytes in blood. T SPOT-TB assay is a test that detects a number of T lymphocytes 
that produce IFN- γ in the blood samples upon TB infection (Mazurek et al., 2003; Meier 
et al., 2005). However, these tests are very costly and cannot be easily performed in 
resource-limited settings and developing countries such as Malaysia. 
 
1.6.3  BCG vaccine and new vaccine candidates 
A good vaccine is a prerequisite for the control, prevention and eventual 
elimination of tuberculosis. Bacillus of Calmette and Guérin (BCG, named after the two 
Frenchmen that developed it), is a live attenuated vaccine that is currently available.  
 
The efficacy of BCG vaccination has shown to be highly variable across different 
populations (Haile and Källenius, 2005). BCG vaccination is widely used in children for 
prevention of primary TB infection such as military TB, but its effectiveness in 
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preventing adult pulmonary TB varies from 0 % to nearly 80 % (Aronson et al., 2004; 
Young and Dye, 2006). Even though the effectiveness of BCG vaccination is varied, it 
has been continually used to protect severe forms of TB in children. Therefore, an 
improvement of the current BCG vaccine is urgently needed. Several factors need to be 
considered when generating a new version of BCG vaccine, i.e. it can be used for:  
a) protection of pre-exposure and post-exposure to M. tuberculosis individuals;  
b) latently infected and healthy individuals;  
c) combination of immunotherapeutic agent with antimicrobials to booster the 
eradication M. tuberculosis;  
d) minimizing the side effect of the individuals who had vaccinated.  
 
In general, the new generation of vaccines should be compatible to BCG and HIV 
patients (Vuola et al., 2003). 
 
Recently, subunit and live vaccine approaches have been widely used to improve 
the TB vaccine. Subunit vaccines can deliver immunodominant Mycobacteria antigens 
such as ESAT-6 (6 kDa early secretory antigenic target). Live vaccines which focus 
mainly in the recombinant engineering of existing BCG strains are hope to improve 
expression of the immunodominant antigens and inactivate the virulence genes of M. 
tuberculosis (Britton and Palendira, 2003). Currently, several new generations of 
vaccines are being developed at the laboratory level.  
 
Studies on multi-variant antigens in recombinant BCG (rBCG) against numerous 
pathogens have shown protective immune response in animal models (Winter et al., 1995; 
Ohara and Yamada, 2001; Santangelo et al., 2007). rBCG is an insertion of targeted 
DNA from one species into the DNA of another. rBCG in the cytokine genes (IL-2, IFN-
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γ) is to improve the immune-stimulatory properties of BCG (Murray et al., 1996) 
whereas the insertion of listeriolysin gene from Listeria monocytogenes to the rBCG is to 
present the microbial antigen to the host cytoplasm in order to enhance the production of 
CD8+ (Hess et al., 1998; Eddine and Kaufmann, 2005). A vaccine developed from 
heterologous prime-boost immunization strategies is being studied as an alternative way 
to boost the immunity. Furthermore, acellular vaccines (virus vaccine) have shown to 
give a better protection than BCG in preclinical testing. For example, a recombinant 
modified vaccinia virus that expresses M. tuberculosis antigen 85A had been investigated 
to be a booster of BCG vaccine. This vaccine was named Ankara vaccine (McShane and 
Hill, 2005; McShane et al., 2004). 
 
In view of the fact that the majority of the targeted vaccine candidates are made 
up of virulence proteins, therefore proteomic investigation in M. tuberculosis for 
identification of virulence proteins in TB is the upmost important. 
 
1.7 M. tuberculosis H37Rv and H37Ra 
M. tuberculosis H37 is a clinical strain that was first isolated by Edward R. 
Baldwin from a 19 year-old male patient with chronic pulmonary TB in 1905 (Steenken 
and Gardner, 1946). Both M. tuberculosis H37Ra and M. tuberculosis H37Rv were 
derived from the same virulent parent strain M. tuberculosis H37 through a process of 
aging and dissociation in vitro culture as demonstrated in Figure 1.6 (Steenken, 1935). 
The parental virulent M. tuberculosis H37 was inoculated onto solid egg media and 
incubated for 3-4 months at 37 °C until the culture dried, discrete colonies lysed and 
transformed into a confluent viscous mass. Then a secondary growth of M. tuberculosis 
emerged with different colony morphology from the midst of the viscous mass. The new 
growth was isolated into fresh media and infected into guinea pigs, but the guinea pigs 
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showed no symptom of TB infection (Steenken, 1935; Steenken, 1938). M. tuberculosis 
H37Ra (‘a’ for avirulent) also has a decrease ability to survive in macrophages or 
anaerobic conditions as compared to its parent strain. Therefore, the laboratory strain has 
lost its virulence, and has some different phenotypes from its virulent sibling M. 
tuberculosis H37Rv [(‘v’ for virulent) (Steenken and Gardner, 1946)]. Consequently, M. 
tuberculosis H37Ra and M. tuberculosis H37Rv have been widely used as laboratory 
reference strains for studying and understanding the virulence and pathogenesis of M. 
tuberculosis worldwide (Zheng et al., 2008). Therefore, a comparison of proteomes 
between MTB H37Ra and H37Rv would shed light in the understanding of the 
pathophysiology of both strains and also in the understanding of protein that could be 
involved in the avirulent pathway. 
 
 
Figure 1.6 The process of M. tuberculosis strain evolution (Adapted from Zheng et 
al., 2008).  
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1.8  The complete genome of Mycobacteria 
The availability of complete genome sequence of M. tuberculosis H37Rv in 1998 
was a big step forward for TB research (Cole et al., 1998). Subsequently, complete 
genome sequences of the clinical isolates, M. tuberculosis CDC1551 (Fleischmann et al., 
2002) and M. bovis AF2122/97 (Garnier et al., 2003) were also being established. 
Recently, the genome sequence of M. tuberculosis H37Ra has also been reported (Zheng 
et al., 2008) and the database of M. tuberculosis H37Ra could be obtained from 
http://cmr.jcvi.org/cgi-bin/CMR/GenomePage. The complete genome of M. tuberculosis 
H37Rv comprises of 4,411,529 base pairs with approximately 4,000 genes, accounting to 
91 % of the potential coding capacity (Brosch et al., 1998; Cole et al., 1998). The 
genomic deoxyribonucleic acid (DNA) consists of 65.5 % of guanine (G) and cytosine (C) 
(Cole et al., 1998). 
 
More than 20 % of M. tuberculosis chromosome consists of fatty acid metabolism; 
acidic, glycine-rich polypeptides; proline-glutamic acid (PE) and proline-proline-
glutamic acid (PPE) proteins family. Forty percent of the M. tuberculosis proteome 
consisting of proteins with known functions were mainly responsible for its metabolism 
pathway. The repetitive DNA (~ 51 %) of M. tuberculosis is due to recent evolution 
descent or extensive functional redundancy of the organism (Cole et al., 1998). 
 
In addition, some genomic regions of TB have been detected as deletions in both 
virulent Mycobacteria and attenuated Mycobacteria. By using DraI digestion, it was 
found that a 480 kb fragment in M. tuberculosis H37Rv is replaced by two fragments of 
220 and 260 kb in M. tuberculosis H37Ra. On the other hand, the 7.9 kb fragment was 
detected in M. tuberculosis H37Ra but not in M. tuberculosis H37Rv (Cole et al., 1994; 
Brosch et al., 1999). Several studies were focused in different genomic regions of 
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virulent M. tuberculosis, M. bovis and avirulent BCG (Mahairas et al., 1996; Brosch et 
al., 1998; Behr et al., 1999), some deletion regions have been identified but the role of 
deleted genes remains unclear.  
 
1.9  Proteomic study 
Proteomics is a study of all proteins in a cell that are translated in a given 
physiological condition. The proteome of an organism refers not only to characterization 
of proteins but also the translation rate and the posttranscriptional events that occur in the 
organism (Betts, 2002). A proteomic study in pathogenic bacteria may result in the 
discovery of potential biomarkers for the identification and monitoring of the disease 
progression. 
 
1.9.1 Current strategy in proteomic study  
The combination of two dimensional electrophoresis (2-DE) and liquid 
chromatography in tandem with mass spectrometry (LC-MS/MS) is widely used in 
studying proteomic. Electrophoresis is the movement of charged particles or molecules 
under the influence of an electric field. Two dimensional electrophoresis (2-DE) 
comprises of two protein separation modes, namely isoelectric focusing for separation of 
proteins according to isoelectric points (pI) and then SDS-PAGE for separation of 
proteins by molecular weights (Nelson and Cox, 2005; Weiss and Görg, 2009). Hence, 
the information obtained from the 2-DE is not only on molecular size but also the charge 
of protein. Two dimensional electrophoresis is very useful in resolving the complex 
mixtures of protein samples. One has to be aware that 2-DE separated proteins with 
differential electrophoretic mobilities may not solely represent the proteins encoded by 
different open reading frames (ORFs); they may also be identified as proteins with 
similar ORF but with a diversification of a primary translation product by co- and 
21 
 
posttranslational protein modifications. The early 2-DE on Mycobacteria has led to 
detection of 50-300 protein spots (Britton et al., 1987; Daugelat et al., 1992; Wallis et al., 
1993; Lee and Horwitz, 1995; Mahairas et al., 1996; Rosenkrands et al., 2000b). 
Currently, the use of chemical modification and immobilized pH gradients in the first 
dimension of 2-DE has increased gel resolution that lead to the detection of 2000 protein 
spots (Urquhart et al., 1997; Sonnenberg and Belisle, 1997; Celis et al., 2006; Wittmann-
Liebold et al., 2006). 
 
The targeted protein spot can be subjected to in-gel enzyme digestion and the 
resulting peptides can be identified using LC-MS/MS. Reverse-phase liquid 
chromatography (LC) is commonly applied in the analysis of proteins and peptides 
(Hancock et al., 1978; Davis and Lee, 1992; Ausubel et al., 2002; Simpson, 2003). The 
principle of reverse phase LC is based on the use of stationary phase that is non-polar 
material [silica linked with carbon-18 (C18)] and the mobile phase that is polar solvent 
(water, methanol, acetonitrile and IPA). Reverse-phase LC aids in the removal of 
contaminants that might interfere with MS/MS analysis (Shaw, 1994). Basically, the 
separation of peptides in reverse-phase LC is based on the strength of hydrophobic 
interaction between the amino acid side chains of the peptides and the stationary phase 
(Stone and Williams, 2002). The elution of binding peptides is based on the gradually 
increasing strength of the organic solvent over a period of time thus resulting in 
concentrated and purified peptides. In the reverse phase LC, the non-polar peptides elute 
slower than the polar compounds in the column (Simpson, 2003). 
 
 
 
22 
 
Electrospray ionization mass spectrometry (ESI-MS) is one of the methods to 
accomplish mass determination of biomolecules (Figure 1.7). The principle of 
electrospray ionization mass spectrometry is the use of soft ionization techniques in order 
to determine the mass of biomolecules. ESI-MS consists of 4 main components:  
1) ionization source;  
2) ion trap mass analyzer;  
3) ion detector and  
4) data processor.  
 
 
Figure 1.7 The structure of ESI-MS (Reproduced with permission from Agilent 
Technologies). 
 
 
A solution of sample and solvent is sprayed through a capillary with a low flow 
rate (0.1-10 µL/min) by applying a high voltage (2-6 kV). This high-voltage could 
increase the charge density at the surface of the droplets and the solvent is evaporated by 
heated drying gas. Therefore, the ions are formed as a result of coulombic repulsion in a 
high-voltage electrostatic gradient (Iribarne and Thomson, 1976). The difference in 
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pressure between the ionization source and the ion transport and focusing region pushes 
the ions through glass capillary. Subsequently, the ions are focused as through ion trap 
mass analyzer to ion detector.  
 
Within the ion trap mass analyzer, the ions are collected and stored for further 
MS/MS analysis by controlling the radio frequency (RF) devices. Helium gas is used for 
efficient trapping and cooling of the ions generated by the electrospray interface. The 
helium pressure in the trap is set by mechanical pressure regulator in order to control the 
helium gas amount. In full scan mode, the RF voltage on the electrodes is changed to 
sequentially eject the ions based on their m/z values. This produces a spectrum that 
represents all peptide ions in the trap. In MS/MS mode, the targeted precursor ions are 
trapped in the ion trap and ejected out all the unwanted ions by manipulating the radio 
frequency. During isolation of target precursor ion, the electronics system on the ion trap 
generates a broadband frequency spectrum with target mass resonating frequency. The 
target precursor ion then undergoes induction fragmentation when the frequency 
increases resulting in collision induction dissociation of the target ions to forming 
product ions, which are scanned according to their m/z values (Liebler, 2002). 
 
1.9.2 Proteomic study of pathogenic and non-pathogenic bacteria 
Comparison proteomic studies of pathogenic and non-pathogenic bacteria are 
widely used in order to detect vaccine candidates or biomarkers for diagnosis and 
treatment of the disease. In general, proteomics studies are involved separation of 
proteins in one- or two- dimensional polyacrylamide gel electrophoresis (Nagai et al., 
1991; Garbe et al., 1996) followed by analysis of proteins using tandem mass 
spectrometry. It is a widely used method to allow fast overview of changes in cell 
processes by analysis of cell’s proteome. To date, the development of high-resolution 2-
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DE systems and highly sensitive mass spectrometric techniques has led to high 
throughput screening of pathogen’s functional genomics in different cell conditions. 
 
The early comparison studies of virulent and avirulent Mycoplasma pneumoniae 
isolates were carried out by (Hansen et al., 1979) and (Hansen et al., 1981). The former 
study identified three novel proteins expressed by the Mycoplasma pneumoniae M129 
virulent isolates. The latter was the comparison study of a virulent parental strain of M. 
pneumonia M129 with two derived avirulent chemical mutant strains. The study reported 
the differential expressed protein at quantitative and qualitative levels when analyzed by 
2-DE. However, no data was provided in the identities of these proteins. 
 
A similar approach was used to compare Brucella. abortus virulent strain 2308, 
avirulent vaccine strain S19 and LPS deficient strains by using 2-DE (Sowa et al., 1992). 
Approximately 935 proteins were resolved by 2-DE although 2129 proteins were 
expected based on the size of the 3.13×106-bp B. abortus genome (Allardet-Servent et al., 
1991). The comparison of the 2-DE protein profiles of the virulent and avirulent strains 
has resulted in the discovery of 86 differentially expressed proteins and 6 unique proteins. 
 
Vibrio vulnificus is a food borne pathogen. The virulence-related proteins of this 
bacterium were ToxR and ToxS. In order to further understanding the pathophysilogy 
pathway, Lee and his co-workers compared the proteome of wild-type Vibrio vulnificus 
and toxR mutant of V. vulnificus (Lee et al., 2006). They found that 12 proteins were 
either up- or down-regulated in the toxR mutant and these proteins may regulate the 
expression of toxR.  
 
In another study, the proteomes of Francisella tularensis virulent subspecies 
tularensis strain SCHU S4 and subspecies holarctica strain were compared. Pavkova et 
